Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can GLP-1 drugs improve heart function during exercise in Obesity-Related heart failure?

NCT ID NCT07787936

Knowledge-focused Sponsor: Miedziowe Centrum Zdrowia SA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This observational study follows people with obesity-related heart failure to see how their heart performs during exercise, using stress echocardiography. It observes those who are taking GLP-1/GIP receptor agonists (like semaglutide or tirzepatide) as part of their routine care, comparing them to those who are not. The goal is to track changes in heart function over a year and explore whether these medications might be linked to improvements.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GLP-1/GIP receptor agonists (e.g., semaglutide, tirzepatide) as observed exposure, not assigned
What this could lead to
If successful, this could reveal how these medications affect heart function during exercise in people with obesity-related heart failure, potentially guiding future treatment approaches.
What could go wrong
This is an observational study, so it cannot prove cause and effect. Results may be influenced by factors like patient selection and may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Jan 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Unselected patients with obesity-related HFpEF managed in a heart failure and cardiology outpatient clinic, enrolled regardless of whether they receive GLP-1/GIP receptor agonist therapy. Obesity-related HFpEF is defined by chronic heart failure symptoms or exertional dyspnea, BMI at least 30 kg/m2, LVEF at least 50%, and objective evidence of HFpEF (no low-probability result on either the H2FPEF or HFA-PEFF score), without a dominant alternative cause of dyspnea.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age 18 years or older Body mass index (BMI) 30 kg/m2 or greater Symptomatic exertional dyspnea, fatigue, or reduced exercise tolerance Left ventricular ejection fraction 50% or greater Probable or established HFpEF per the diagnostic score algorithm (no low-probability result on either the H2FPEF or HFA-PEFF score) Able to perform semi-supine bicycle exercise echocardiography Written informed consent for registry participation and data processing Exclusion Criteria: Significant valvular heart disease Cardiomyopathy other than the typical HFpEF phenotype (suspected amyloidosis, restrictive or hypertrophic cardiomyopathy as the primary problem) Recent acute decompensated heart failure or recent hospitalization for heart failure Unstable coronary artery disease Severe pulmonary disease as the primary cause of dyspnea Severe anemia or another systemic cause of exercise limitation Inability to safely perform an exercise test Very poor echocardiographic window precluding any analysis Active malignancy or gynecological condition that may substantially affect CA-125 (diagnosed endometriosis, pelvic inflammatory disease, suspected ovarian tumor, significant non-cardiac ascites) Absence of consent for registry participation and data processing

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diastolic heart failure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure Iron Deficiencies iron deficiency anemia Obesity obesity disorder pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diastolic heart failure Heart failure with preserved ejection fraction Iron-deficiency Obesity Pulmonary hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Klinika Kardiologii, Miedziowe Centrum Zdrowia SA

    Lubin, Lower Silesian Voivodeship, 59-300, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.